Jessica Serra | Head of Investor Relations & ESG |
Mark Foley | Chief Executive Officer |
Dustin Sjuts | President |
Tobin Schilke | Chief Financial Officer & Principal Accounting Officer |
Chris Shibutani | Goldman Sachs |
Ken Cacciatore | Cowen |
David Amsellem | Piper Sandler |
Stacy Lee | Stifel |
Justin Phillips | Morgan Stanley |
Rohit Bhasin | Needham & Company |
Welcome to the Revance Therapeutics Third Quarter 2022 Financial Results and Corporate Update Conference Call. At this time, all participants are in a listen-only mode.
Following managements' prepared remarks, we will hold a question-and-answer session. [Operator Instructions] As a reminder, this call is being recorded today, Tuesday, November 8, 2022. I would now like to turn the conference call over to Jessica Serra, Head of Investor Relations and ESG for Revance.